crenolanib + cytarabine + daunorubicin

This drug regimen is a **combination therapy** consisting of **crenolanib**, **cytarabine**, and **daunorubicin**, currently studied for the treatment of **newly diagnosed FLT3-mutant acute myeloid leukemia (AML)**. Crenolanib is a second-generation small molecule inhibitor specifically targeting FLT3 mutations, including both internal tandem duplications (ITD) and tyrosine kinase domain (TKD) mutations. Cytarabine is a cytotoxic antimetabolite (pyrimidine analog) and daunorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II. This combination is typically administered as a “7+3” induction regimen (cytarabine for 7 days, daunorubicin for 3 days) followed by crenolanib, with further consolidation and maintenance phases. The addition of crenolanib to conventional chemotherapy aims to improve remission rates and long-term outcomes in patients with FLT3-mutant AML by sustained inhibition of FLT3 signaling. This triple therapy regimen is investigational and not yet approved by regulatory agencies[1][2][3][4][5].